Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
v2amWQjUS4XpqdeJ